Trial Profile

A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UB 612 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors United Biomedical

Most Recent Events

16 May 2022 Results of an interim safety and immunogenicity of phase I until 14 days after the third (booster) dose published in the Journal of Clinical Investigation
06 Apr 2022 Results presented in an United Biomedical Media Release.
06 Apr 2022 According to an United Biomedical media release, data published in the Journal of Clinical Investigation.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com